Skip to main content
IMUX logo

IMUX · Immunic, Inc.

Track IMUX — free
$7.25 -0.27 (-3.59%)
Market Cap
$117.36M
Shares
15.88M
Volume · Nov 19 388.39K Avg daily vol (3M) 339.26K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.39 Open$7.55 Day$7.08–7.82 52W close$5.10–16.90 Avg vol 30d287K Short int2.0M · 12.3% of shares · 5.7d Short vol51% Last earningsNov 13, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 13

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks
call held Nov 7, 2024

Latest documents

2026
Nov 13
Current report 8-K
ENSURE top-line data on track for December 2026

Immunic said fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials remain on track for December 2026 top-line data; third-quarter net loss was approximately $42.3 million, and $132.0 million cash is expected to fund operations into late 2027.

Financial results
3 source passages
Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials remains on track and is expected to be available in December 2026. Net Loss for the three months ended September 30, 2026, was approximately $42.3 million, or $0.99 per basic and diluted share, based on 42,797,370 weighted-average common shares outstanding, compared to a net loss of approximately $25.6 million, or $1.32 per basic and diluted share, based on 19,389,776 weighted-average common shares outstanding for the same period ended September 30, 2025. Cash and Cash Equivalents as of September 30, 2026 were $132.0 million. Based on its current operating plan, Immunic expects that these funds will be sufficient to fund its operations into late 2027. Open the document at this passage
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ENSURE top-line data expected in December 2026

Immunic expects ENSURE top-line data for vidofludimus calcium in December 2026. Cash and cash equivalents of approximately $132.0 million as of September 30, 2026 are expected to fund operations beyond twelve months.

Net loss $42.31M Diluted EPS -$0.99
Read from the MD&A section
2 source passages
The top-line data for both ENSURE trials is expected in December 2026. As of September 30, 2026, we had cash and cash equivalents of approximately $132.0 million. With these funds we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying consolidated financial statements. Open the document at this passage
Nov 10
Investor event
Two pivotal MS trials read out in December

Immunic expects two phase three relapsing MS trials, Insure One and Insure Two, to read out in December, potentially enabling an NDA filing, while initiating the Protect MS progressive-MS study.

3 source passages
I'm Eric Lundgren, the CEO of Immunic. We have two phase three pivotal trials reading out in relapsing MS, the Insure One and Insure Two studies. Those will be reading out in December. And they would be, assuming they're positive, they would be NDA filing enabling. In addition, we are initiating a third phase three study. This one would be in progressive MS. That's called the Protect MS study, getting that off the ground as well. Open the document at this passage
Nov 9
Investor event
Ensure 1 and Ensure 2 readouts precede potential NDA filing

Immunic expects Ensure 1 and Ensure 2 to read out in December; positive results could support an NDA filing and approval in relapsing multiple sclerosis, with filing targeted for the middle of next year.

2 source passages
We have two pivotal trials reading out in December. So we're right around the corner, right on the threshold of that data. These are two studies called Ensure 1 and Ensure 2, and they would, if they're positive, result in an NDA filing and approval in relapsing multiple sclerosis. In terms of filing, middle of next year would be the goal for filing. Open the document at this passage
Nov 5
Current report 8-K
PMS R&D Day scheduled for November 5, 2026

Immunic is hosting a Progressive Multiple Sclerosis Research and Development Day webinar on November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference, during which it plans to present.

Regulation FD disclosure
Source passage
On November 5, 2026, Immunic, Inc. (the “Company” or “Immunic”) is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar (the “PMS R&D Day”). The PMS R&D Day will take place on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$128.30M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-80.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$131.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+120.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
12.3%
Latest settlement · 5.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −36%
below
Price vs 50-day avg −11%
below
RSI (14) 43
neutral
MACD trend Positive
52-week position 19%
mid-range
Momentum
relative strength
Neutral
1-month return +2%
trailing
6-month return −51%
trailing
YTD return +38%
this year
Relative strength −46%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $8 › 200d $12 — 200d above 50d
Institutional flow Accumulating
+38% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.28% of shares out · ▲ +4.8% MoM · 5.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
80 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
EPS growth +38%
Y/Y
Free cash flow $-86.0M
Balance sheet $15.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −61%
past year
ATR 7.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 3, 2023
Cash, Cash Equivalents and Investments (expected to fund operati · into the fourth quarter of 2024 $77.3M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−36% Bearish
Price vs 50-day avg
−11% Bearish
RSI (14)
43 Neutral
MACD trend
Positive Bullish
52-week position
19% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $8 › 200d $12 — 200d above 50d
Institutional flow Accumulating
+38% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.28% of shares out · ▲ +4.8% MoM · 5.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
80 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $7 · 19% Range high $17
vs 200-day avg -36% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
countries 15 Third Quarter 2026 —
ENSURE-1 randomized patients 1,121 Third Quarter 2026 —
ENSURE-2 randomized patients 1,100 Third Quarter 2026 —
patients discontinued 6.5% through the January 27, 2026 data cutoff —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IMUX
Immunic, Inc.
this stock
$117.36M — — — 12.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
80
% held
68.7%
Net QoQ
+2.4M sh
Top holder
Aberdeen Group plc
Held Float
View
Held by Funds
Fund positions
29
View
Short & Settlement
Short Interest Rising
Shares short
2.0M
Days to cover
5.7d
Change
+88.5K sh
View
Short Volume
Short vol %
51%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$29.5K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
49.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-97.2M
EPS diluted
$-6.20
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 13, 2026
This year
34

Immunic expects ENSURE top-line data for vidofludimus calcium in December 2026. Cash and cash equivalents of approximately $132.0 million as of September 30, 2026 are expected to fund operations beyond twelve months.

View
Exempt Offerings
Offering
$200.0M
Filed
Mar 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 13, 2026
View
Investor Relations
Latest news
Immunic, Inc. Reports Third Quart…
Published
Nov 13, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
IMUX -5.1% +2.4% -51.2% -1.6% +38.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +0.3% +8.6% -45.5% +3.7% +33.4%
Key facts CIK 1280776 CUSIP 4525EP200 13F (30d) 97 filings 81 filers Visit website Investor relations